Claus Bachert

Research Statement

AI generated · 2d ago

Claus Bachert's indexed work centers on the inflammatory mechanisms and biologic treatment of chronic rhinosinusitis with nasal polyps. His most-cited first-author trial, dupilumab in severe chronic rhinosinusitis with nasal polyps, reported phase 3 evidence that shaped biologic therapy for the disease (1573 citations), while earlier work on inflammatory endotypes of chronic rhinosinusitis derived by cluster analysis of biomarkers helped reframe the condition as a set of distinguishable immunological subtypes. Related studies on local IgE and eosinophilic inflammation in nasal polyps and on T-effector cell profiles across chronic sinus disease trace a consistent line of inquiry into how mucosal immune signatures define patient groups. Beyond those lead-author studies, Bachert contributed as a co-author to major consensus and guideline outputs, including the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 and the ARIA guidelines for allergic rhinitis and its impact on asthma, documents that standardize definitions and care pathways internationally. No software, datasets, patents, or funded grants are indexed beyond his publications. Across the named works, the arc runs from characterizing inflammatory mediators and endotypes toward testing targeted biologics and codifying that evidence into clinical guidance.

Most Cited Works

EUFOREA consensus on biologics for CRSwNP with or without asthma

Wytske J Fokkens, Valerie Lund, Claus Bachert, Joaquim Mullol, Leif Bjermer, Jean Bousquet, Giorgio W Canonica, Lauren Deneyer, Martin Desrosiers, Zuzana Diamant, Joseph Han, Enrico Heffler, Claire Hopkins, Roger Jankowski, Guy Joos, Andrew Knill, Jivianne Lee, Stella E Lee, Gert Mariën, Benoit Pugin, Brent Senior, Sven F Seys, Peter W Hellings

Allergy2019

391Citations

Research Areas

Asthma and respiratory diseasesSinusitis and nasal conditionsAllergic Rhinitis and SensitizationCystic Fibrosis Research AdvancesNasal Surgery and Airway Studies

Loading ORCID activity...

Sources

Research Statement

Most Cited Works

EUFOREA consensus on biologics for CRSwNP with or without asthma

Research Areas

Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

Non‐allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

2019 ARIA Care pathways for allergen immunotherapy

Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis